Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) [Phase 3]

View source ↗

Summary

This clinical trial update reports a Phase 3 study comparing Sacituzumab Tirumotecan (MK-2870) to chemotherapy in previously treated advanced or metastatic nons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sacituzumab Tirumotecan (MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING